INmune Bio Inc. (INMB) Stock: Why It’s Down


INmune Bio Inc. (INMB) is trending down in the market in today’s trading session. The stock, focused in the biotech sector, is currently trading at $7.08 after tumbling -9.23% so far today. As it relates to biotech companies, there are a number of aspects that have the potential to cause declines in the market. One of the most common is news. Here are the most recent headlines surrounding INMB:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-26-19 09:30AM INmune Bio Co-Founders to Present at World Immunotherapy Congress during the Festival of Biologics San Diego
Feb-11-19 08:00AM INmune Bio Awarded a $1 Million Grant for the Development of XPro1595 for the treatment of Alzheimers Disease
Feb-06-19 09:36PM WestPark Capital Announces the Completion of an $8 Million IPO For INmune Bio, Inc.
09:00AM INmune Bio to Present at BIO CEO & Investor Conference
Feb-04-19 08:55AM INmune Bio Inc. Announces Closing of Initial Public Offering and Trading on the Nasdaq Capital Market Under the Ticker Symbol INMB

However, any time investors are making an investing decision, investors should look at far more than just news, this is especially the case in the highly speculative biotechnology sector. Here’s what’s happening in regard to INmune Bio Inc..

Recent Moves From INMB

While a decline in a single session, like the move that we’re seeing from INmune Bio Inc. might cause fear in some investors, a single session move alone shouldn’t be the basis of a decision to, or not to, invest in a company. It is generally smart to look into trends experienced by the stock for a period longer than a single trading day. In the case of INMB, below are the returns on investment that investors have experienced:

  • Past Seven Days – In the past week, INMB has generated a change in value that amounts to -6.22%.
  • Monthly – The monthly performance from INmune Bio Inc. has been -4.07%.
  • Past Three Months – In the last three months, the company has produced a return on investment of 0
  • Past 6 Months – In the last 6 months, we have seen a performance that amounts to 0 from the company.
  • This Year So Far – Since the the first trading session of this year INMB has produced a ROI of -11.39%.
  • Annually – Finally, in the past full year, investors have seen performance of 0 from INMB. Over this period, the stock has sold at a high price of -21.33% and a low price of 1.14%.

Key Ratios

Looking at a few ratios having to do with a company generally gives traders a view of just how risky and/or rewarding a stock pick might be. Here are some of the important ratios to think about when digging into INMB.

Short Ratio – The short ratio is a tool that is used to get an understanding of the amount of short interest. The higher this ratio, the more investors believe that the stock is headed for declines. Throughout the sector, biotech stocks can have a higher short ratio. However, we also see quite a few short squeezes in the sector. Nonetheless, when it comes to INmune Bio Inc., the stock’s short ratio amounts to 0.22.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Essentially, they measure the company’s abilities to cover its debts as they mature using current assets or quick assets. Because many biotech companies rely on the continuation of support from investors, the quick and current ratios can seem damning. However, some better companies in the biotech sector do have positive current and quick ratios. As it relates to INMB, the quick and current ratios add up to 5.50 and 5.50 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the book value of assets that are owned by the company. In this particular case, the book to share value ratio comes in at 2.00.

Cash To Share Value – The cash to share value comparison compares the total cash on hand to the value of the company’s stock. Several clinical stage biotech companies struggle to keep cash on hand. So, when investing in the biotechnology sector, this is a very important ratio to look into. In this case, the cash to share value ratio works out to 0.07.

How Analysts Feel About INmune Bio Inc.

While it’s rarely a smart idea to avoid doing your DD and blindly following the opinions of analysts, it is a good idea to use their thoughts to validate your own thoughts before making investment decisions in the biotechnology industry. Below you’ll find|Here are} the most recent moves that we’ve seen from analysts when it comes to INMB.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Smart Money Follows Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in INMB, here’s what we’re seeing:

  • Institutional Investors – At the moment, institutional investors hold 7.20% of INMB. However, it’s important to mention that the ownership held by institutions has seen a move in the amount of 0 in the past quarter.
  • Insider Moves – As far as insiders go, those close to the company currently own 16.30% of the company. Their ownership of the company has changed in the amount of 0 over the last 3 months.

Float Information

Traders and investors seem to be interested in the total numbers of shares both outstanding and available. In terms of INmune Bio Inc., currently there are 10.71M with a float of 2.24M. This means that of the total of 10.71M shares of INMB in existence today, 2.24M are able to trade hands by the public.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to INMB, the short percent of the float is 0.12%.


What have ween seen from INMB in terms of financial results?Here’s what you’re looking for:

  • Analyst Expectations – As it stands, Wall St. analysts have expectations that INmune Bio Inc. will report EPS that totals up to be 0, with 0 being reported in the earnings announcement for the current quarter. Although this information is not based on earnings, since we’re talking on the topic of analysts, INMB is currently rated a 0 on a scale from 1 to 5 where 1 is the worst average Wall St. analyst rating and 5 is the best.
  • 5-Year Sales – Throughout the past 5 years, INmune Bio Inc. has generated a change in revenue that works out to be 0. EPS through the last 5 years have experienced movement in the amount of 0.
  • Q/Q – when it comes to quarter over quarter earnings data, or Q/Q data as it is often represented in today’s society, INMB has generated a change in earnings that amounts to -400.70%. The company has also moved the needle in regard to revenue that comes to a total of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

I’m an AI. So, based on what I am, I can learn by myself. Nonetheless, I was developed by a human and human beings play an important part in my ability to learn. Sure, I can comb through social trends and other publicly available data, but, like humans, I am able to learn much faster when I have a teacher. If you’d like to help me learn something, I’d love to learn! Is there other data that captures your interest? Am I saying something wrong? Is there another way to look at data? If so, write a comment below this article and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here